Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BNTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Gotistobart | Non Small Cell Lung Cancer | Phase 3 · NCT05671510 | Active not recruiting |
| CAPOX | Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 · NCT07221357 | Recruiting |
| Elfetabart Drozuntecan (DB-1311) | Metastatic Castration-resistant Prostate Cancer | Phase 3 · NCT07365995 | Recruiting |
| Trastuzumab Pamirtecan (BNT323) | Endometrial Cancer | Phase 3 · NCT06340568 | Recruiting |
| Nab-paclitaxel | Metastatic Breast Cancer | Phase 3 · NCT06018337 | Active not recruiting |
| FOLFOX | Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 · NCT07221357 | Recruiting |
| FOLFIRI | Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 · NCT07221357 | Recruiting |
| Tozinameran | COVID-19 | Phase 3 · NCT07300839 | Completed |
| Doxorubicin | Endometrial Cancer | Phase 3 · NCT06340568 | Recruiting |
| HPV16 E6/7 mRNA Vaccine BNT113 | Unresectable Head and Neck Squamous Cell Carcinoma | Phase 2/3 · NCT04534205 | Active not recruiting |
| Prednisolone | Metastatic Castration-resistant Prostate Cancer | Phase 3 · NCT07365995 | Recruiting |
| Trastuzumab Emtansine | HER2-positive Breast Cancer | Phase 3 · NCT06265428 | Active not recruiting |
| Eribulin | Breast Neoplasms | Phase 3 · NCT07173751 | Recruiting |
| Pumitamig (BNT327) | Extensive-stage Small-cell Lung Cancer | Phase 3 · NCT06712355 | Recruiting |
| Tecaginlimab (GEN1042) | Non-CNS Tumor | Phase 1/2 · NCT05491317 | Terminated |
| Anti-OX40 Agonist Monoclonal Antibody GEN1055 | Malignant Solid Tumor | Phase 1/2 · NCT06391775 | Terminated |
Also used in these trials (approved or third-party drugs, not BNTX's own candidates): Pemetrexed Disodium, Capecitabine, Carboplatin, Nivolumab, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Durvalumab, Atezolizumab, Bevacizumab, Docetaxel Anhydrous, Etoposide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BNTX holds $13.7B in cash and short-term investments and burns about $57.7M/quarter from operations, an estimated runway of 712.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BNTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| ATHOS KG | 5%+ holder (13G) | 101,702,378 | 40.49% | 2026-03-31 |
| Ugur Sahin Chief Executive Officer, 10% owner |
Insider | 39,218,111 | 15.61% | 2026-10-08 |
| Helmut Wolfgang Jeggle Director |
Insider | 989,267 | 0.39% | 2026-03-18 |
| Sierk Poetting Chief Operating Officer · +22,655 options |
Insider | 399,387 | 0.16% | 2026-04-22 |
| James Timothy Patrick Ryan Chief Legal Officer and Chief Business O · +22,655 options |
Insider | 4,795 | 0.00% | 2026-03-18 |
| Ulrich Wandschneider Director |
Insider | 1,927 | 0.00% | 2026-03-18 |
| Rudolf Staudigl Director |
Insider | 400 | 0.00% | 2026-03-18 |
| Anja Morawietz Director |
Insider | 240 | 0.00% | 2026-03-18 |
Share count 251,204,366 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BNTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →